TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Terminated
Trial end date:
2019-12-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of TAK-659 measured by independent
radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with
relapsed or refractory DLBCL.